← Eichor
Condition: Appendiceal Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Appendiceal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Phase 2 · 2 location(s) · Prakash Pandalai · NCT04779554Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Phase 2 · 1 location(s) · University of California, Irvine · NCT07693452Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 9 location(s) · Apollo Therapeutics Ltd · NCT06399757A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06207305Molecular Profiling for Risk Stratification in Appendiceal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07587268A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherap
NA · 1 location(s) · Yale University · NCT07291180Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Genetics of Appendix Cancer Study
Phase N/A · 1 location(s) · Andreana Holowatyj, PhD, MSCI · NCT05734430A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendice
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05947838Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
NA · 1 location(s) · University of California, Davis · NCT06101277Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05472948
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.